trimebutine

Small moleculeexperimental

Trimebutine is a drug with antimuscarinic and very weak mu opioid agonist effects. It is used for the treatment of irritable bowel syndrome and other gastrointestinal disorders. It is sometimes combined with simethicone as a combination drug. Trimebutine is formulated as a tablet or granules for oral suspension. — Wikipedia

Clinical trial activity

11 trials · 29 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
4
Phase 3
2
Phase 4
3

Earliest trial started Dec 1, 2011 (NCT01507922)

Timeline

2010s

  1. Jan 1, 2012

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2013

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2013

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(c1ccccc1)N(C)C
Mol. weight
387.48 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 2-dimethylamino-2-phenylbutyl 3,4,5-trimethoxybenzoat
  • 2-dimethylamino-2-phenylbutyl 3,4,5-trimethoxybenzoat
  • gic-1001
  • gic-1001
  • gic-1001
  • timebutine
  • trimebutine
  • trimebutine
  • trimebutine
  • trimebutine
  • trimebutine
  • trimebutine
  • (+/-)-trimebutine
  • trimébutine
  • trimébutine
  • trimebutine 3-thiocarbamoylbenzenesulfonate
  • trimebutine maleate
  • trimebutine maleate
  • trimebutine maleate
  • trimebutine maleate
  • trimebutine maleate
  • trimebutine maleate
  • trimebutine maleate
  • trimebutino
  • trimebutino

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06842966Phase 2Oct 17, 2024Valenta Pharm JSC
NCT06268964Phase 1/Phase 2 (Phase 2)Sep 1, 2024Universidad de Colima
NCT04403087Phase 4Jun 1, 2020Hallym University
NCT03359499Phase 2/Phase 3 (Phase 3)Aug 12, 2017Hospital Britanico
NCT03036111N/AFeb 1, 2017Mansoura University
NCT02986685Phase 4Nov 1, 2016Ankang City Central Hospital, Baoji Central Hospital, Hanzhong Central Hospital, People's Liberation Army of China, Shaanxi Provincial People's Hospital
NCT02276768Phase 1Oct 1, 2014Algorithme Pharma Inc, gicare Pharma Inc.
NCT01984931Phase 3Oct 1, 2013Chungmu Hospital, CM Chungmu Hospital, Korea United Pharm. Inc.
NCT01926444Phase 2Jul 1, 2013Algorithme Pharma Inc, Anaheim Clinical Trials, Avail Clinical Research, Gastroenterology Associates of Orangeburg, SC, gicare Pharma Inc., JSS Medical Research Inc., Mayo Clinic, Mid-Atlantic Medical Research Centers, Hollyword, MD, PharmaTrials, Precision Research Institute, The Center of GI Disorders, Hollwood, FL, USA, Toronto Digestive Disease Associates, Toronto, ON, Canada, University of British Columbia, Yeshiva University
NCT01738425Phase 1Nov 1, 2012Algorithme Pharma Inc, gicare Pharma Inc.
NCT01507922Phase 4Dec 1, 2011Bukwang Pharmaceutical, Korea University
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (29)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Algorithme Pharma IncFor profit3022012
gicare Pharma Inc.For profit3322012
Anaheim Clinical TrialsFor profit1012013
Ankang City Central HospitalAcademic/Hospital1012016
Avail Clinical ResearchFor profit1012013
Baoji Central HospitalAcademic/Hospital1012016
Bukwang PharmaceuticalFor profit1112011
Chungmu HospitalAcademic/Hospital1012013
CM Chungmu HospitalAcademic/Hospital1112013
Gastroenterology Associates of Orangeburg, SCAcademic/Hospital1012013
Hallym UniversityAcademic/Hospital1112020
Hanzhong Central HospitalAcademic/Hospital1012016
Hospital BritanicoAcademic/Hospital1112017
JSS Medical Research Inc.For profit1012013
Korea United Pharm. Inc.For profit1012013
Korea UniversityAcademic/Hospital1012011
Mansoura UniversityAcademic/Hospital1112017
Mayo ClinicAcademic/Hospital1012013
Mid-Atlantic Medical Research Centers, Hollyword, MDAcademic/Hospital1012013
People's Liberation Army of ChinaGovernment1112016
29 organizations
Page 1 / 2